| 发明名称 | Drug delivery system | ||
| 摘要 | An ocular drug delivery system comprising a photocaged drug comprising a therapeutic agent that is rendered biologically inactive by being coupled to a protective ligand or caging group by a photocleavable bond, with the therapeutic agent being capable of being activated and/or released in response to a predetermined wavelength and/or intensity of light which breaks the photocleavable bond. | ||
| 申请公布号 | US8951547(B2) | 申请公布日期 | 2015.02.10 |
| 申请号 | US201313939528 | 申请日期 | 2013.07.11 |
| 申请人 | Lumemed Limited | 发明人 | Whitmore Alan |
| 分类号 | A61F9/00;A61N2/10;A61N5/01;A61K9/14;A61N2/00;A61K9/00;A61N2/06;A61K41/00 | 主分类号 | A61F9/00 |
| 代理机构 | Senniger Powers LLP | 代理人 | Senniger Powers LLP |
| 主权项 | 1. An ocular drug delivery system comprising: a photocaged drug comprising a therapeutic agent that is rendered biologically inactive by being coupled to a protective ligand or caging group by a photocleavable bond; wherein said therapeutic agent is capable of being activated and/or released in response to a predetermined wavelength and/or intensity of light which breaks said photocleavable bond; wherein said photocaged drug is coupled to a superparamagnetic nanoparticle; and wherein the system is suitable for delivering the drug to an eye; and wherein said therapeutic agent is capable of being activated and/or released in response to visible light having a wavelength from 400 nm to 1000 nm which breaks said photocleavable bond. | ||
| 地址 | Warden, Northumberland GB | ||